Semaglutide

From WikiMD's Wellnesspedia

What is Semaglutide?[edit | edit source]

Semaglutide (OZEMPIC) is a glucagon-like peptide 1 (GLP-1) receptor agonist.


Semaglutide.svg

What are the uses of this medicine?[edit | edit source]

This medicine is used

  • along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
  • to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease.

Limitations of Use:

How does this medicine work?[edit | edit source]

  • Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1.
  • Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
  • The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation.
  • Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme.
  • Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner.
  • Thus, when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited.
  • The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Who Should Not Use this medicine ?[edit | edit source]

This medcine cannot be used in patients if:

Symptoms of a serious allergic reaction include:

  • swelling of your face, lips, tongue or throat
  • problems breathing or swallowing
  • severe rash or itching
  • fainting or feeling dizzy
  • very rapid heartbeat

What drug interactions can this medicine cause?[edit | edit source]

  • Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin may increase the risk of hypoglycemia.
  • OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.

Is this medicine FDA approved?[edit | edit source]

  • It was approved for use in the United States in 2017.

How should this medicine be used?[edit | edit source]

Recommended Dosage

  • Start OZEMPIC with a 0.25 mg subcutaneous injection once weekly for 4 weeks.
  • The 0.25 mg dose is intended for treatment initiation and is not effective for glycemic control.
  • After 4 weeks on the 0.25 mg dose, increase the dosage to 0.5 mg once weekly.
  • If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose, the dosage may be increased to 1 mg once weekly.
  • The maximum recommended dosage is 1 mg once weekly.

Administration

  • Use OZEMPIC exactly as your healthcare provider tells you to.
  • Your healthcare provider should show you how to use OZEMPIC before you use it for the first time.
  • OZEMPIC is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Do not inject OZEMPIC into a muscle (intramuscularly) or vein (intravenously).
  • Use OZEMPIC 1 time each week, on the same day each week, at any time of the day.
  • You may change the day of the week you use OZEMPIC as long as your last dose was given 2 or more days before.
  • If you miss a dose of OZEMPIC, take the missed dose as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day.
  • OZEMPIC may be taken with or without food.
  • Do not mix insulin and OZEMPIC together in the same injection.
  • You may give an injection of OZEMPIC and insulin in the same body area (such as your stomach area), but not right next to each other.
  • Change (rotate) your injection site with each injection. Do not use the same site for each injection.
  • Check your blood sugar as your healthcare provider tells you to.
  • Stay on your prescribed diet and exercise program while using OZEMPIC.
  • Talk to your healthcare provider about how to prevent, recognize and manage low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and problems you have because of your diabetes.
  • Your healthcare provider will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.
  • Do not share your OZEMPIC pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Injection:

2 mg/1.5 mL (1.34 mg/mL) available in:

  • Single-patient-use pen that delivers 0.25 mg or 0.5 mg per injection.
  • Single-patient-use pen that delivers 1 mg per injection.

4 mg/3 mL (1.34 mg/mL) available in:

  • Single-patient-use pen that delivers 1 mg per injection

This medicine is available in fallowing brand namesː

  • OZEMPIC

What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

  • nausea
  • vomiting
  • diarrhea
  • stomach (abdominal) pain
  • constipation

OZEMPIC may cause serious side effects, including:

  • inflammation of your pancreas (pancreatitis)
  • changes in vision
  • low blood sugar (hypoglycemia)
  • kidney problems (kidney failure)
  • serious allergic reactions

What special precautions should I follow?[edit | edit source]

  • Pancreatitis has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
  • Diabetic retinopathy complications has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored.
  • Never share an OZEMPIC pen between patients, even if the needle is changed.
  • Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary.
  • Acute kidney injury may occur. Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.
  • Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue OZEMPIC if suspected and promptly seek medical advice.

What to do in case of emergency/overdose?[edit | edit source]

  • In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
  • A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of OZEMPIC of approximately 1 week.

Can this medicine be used in pregnancy?[edit | edit source]

  • There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Can this medicine be used in children?[edit | edit source]

  • Safety and efficacy of OZEMPIC have not been established in pediatric patients (younger than 18 years).

What are the active and inactive ingredients in this medicine?[edit | edit source]

  • Active Ingredient: semaglutide
  • Inactive Ingredients: disodium phosphate dihydrate, propylene glycol, phenol and water for injection

Who manufactures and distributes this medicine?[edit | edit source]

  • Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark

OZEMPIC® is a registered trademark of Novo Nordisk A/S.

What should I know about storage and disposal of this medication?[edit | edit source]

  • Prior to first use, OZEMPIC should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC).
  • Do not store in the freezer or directly adjacent to the refrigerator cooling element.
  • Do not freeze OZEMPIC and do not use OZEMPIC if it has been frozen.
  • After first use of the OZEMPIC pen, the pen can be stored for 56 days at controlled room temperature (59°F to 86°F; 15°C to 30°C) or in a refrigerator (36°F to 46°F; 2°C to 8°C).
  • Do not freeze.
  • Keep the pen cap on when not in use.
  • OZEMPIC should be protected from excessive heat and sunlight.
  • Always remove and safely discard the needle after each injection and store the OZEMPIC pen without an injection needle attached.
  • Always use a new needle for each injection.
Semaglutide Resources

Find a healthcare provider anywhere in the world quickly and easily!

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

WikiMD.png


WikiMD is the world's largest, free medical and wellness encyclopedia edited only by professionals. Advertise!


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.